Insulin Degludec
Brand names: Insulin Degludec, Insulin Degludec Pen (U-100), Insulin Degludec Pen (U-200), Tresiba, Tresiba Flextouch U-100, Tresiba Flextouch U-200
Part of: Insulin
At a glance
- Medicare prescriptions, 2024
- 1,586,287
- Medicare drug cost
- $1.29B
- Average cost per prescription
- $813
- Clinicians who prescribed it
- 40,390
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
TRESIBA is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus. Limitations of Use • Not recommended for the treatment of diabetic ketoacidosis.
From the FDA-approved prescribing information (label dated June 2022). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Endocrinology & Diabetes 27.2%
- Family Medicine 22.8%
- Nurse Practitioners 22.0%
- Internal Medicine 18.3%
- Physician Assistants 6.8%
- Geriatric Medicine 0.7%
- General Practice 0.6%
- Pharmacists 0.4%
- Nephrology (Kidney) 0.2%
- Hospitalist 0.2%
- Cardiology 0.1%
- Pediatrics 0.1%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 46% from 2019 to 2024.
Biggest change by state since 2019
- Oregon +93%
- Colorado +85%
- Maine +76%
- Utah +76%
- Arizona +74%
- Minnesota (smallest change) −2%
- Pennsylvania (smallest change) +18%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
Industry payments about this drug
Drug makers reported $7,646 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Novo Nordisk Inc $7,646
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
1 recall since 2020
- Mar 2021 · Novo Nordisk Inc · Class I
Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.